The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by Chardan Capital on December 18, 2024. The analyst firm set a price target for $212.00 expecting KRYS to rise to within 12 months (a possible 42.87% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Krystal Biotech (NASDAQ:KRYS) was provided by Chardan Capital, and Krystal Biotech maintained their buy rating.

The last upgrade for Krystal Biotech Inc happened on February 28, 2023 when Goldman Sachs raised their price target to $124. Goldman Sachs previously had a neutral for Krystal Biotech Inc.

The last downgrade for Krystal Biotech Inc happened on August 6, 2024 when Citigroup changed their price target from $195 to $204 for Krystal Biotech Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.

While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a maintained with a price target of $212.00 to $212.00. The current price Krystal Biotech (KRYS) is trading at is $148.39, which is out of the analyst’s predicted range.